Aetiology of TemporaL Arteritis Study — ATLAS  

Temporal Arteritis Clinical Trial

Official title: Understanding the Aetiology and Pathogenesis of Giant Cell Arteritis

Status Withdrawn

Clinical Trial Summary

Giant Cell Arteritis (GCA) is the most common vasculitis and has significant morbidity in terms of blindness, stroke, and tissue necrosis. It requires protracted treatment with high-dose steroids, and despite this there is a risk of flare during the treatment. Little is known about the initial triggers for the inflammatory process, and there are no good markers of response or relapse. We will study patients referred with suspected GCA to identify important components of the immune response in GCA, and follow them over time to collect evidence of how best to monitor their condition.

Clinical Trial Description

Objectives and Study Plan:

Study Purpose:

The purpose of the study is to investigate the underlying immunological processes in GCA and to study the pattern of expression of immune response over time to give us information about how best to monitor GCA.

End Point:

The end point will be the final visit of the final patient.

Milestones:

The project is in 3 phases. In phase 1 (0-2 years) patients will be recruited to fulfil the specified primary and secondary objectives. In phase 2 (0-4 years), these patients will be followed up for a total of 2 years each, or until they are discharged from clinic. In phase 3 (1-5 years), further studies will be defined and tissue and data collected under amended ethics. ;

Related Conditions & MeSH terms

• Arteritis
• Giant Cell Arteritis
• Temporal Arteritis

• NCT number: NCT02584517
• Study type: Observational
• Source: University of Oxford
• Status: Withdrawn
• Start date: January 2016
• Completion date: January 2021